Hepatitis C News

Brii Biosciences, Vir Biotechnology and VBI Vaccines announced the first patient dosed in a phase 2 trial evaluating combination therapy for the treatment of patients with chronic hepatitis B infection, according to a press release.

With the availability of simple and effective treatment for hepatitis C, specialists are seeking to expand the base of clinicians caring for patients with HCV by exploring new models of care.

These reports include new research on the impact of screening methods, elimination efforts and direct-acting antiviral agents.

Hepatocellular carcinoma rates among people with HIV increased significantly from 1996 to 2015, according to a study published in JAMA Network Open.

A combination of inreach and mailed outreach was an effective hepatitis C screening strategy among hard-to-reach populations, according to study results.

Hepatitis C testing uptake was high and treatment outcomes were good among patients seen at a homeless outreach service in a primary care center in London, according to a study presented at The Liver Meeting Digital Experience.

Patients with hepatitis C who had regular follow-up and those who had delayed follow-up after treatment with direct-acting antiviral agents achieved similar sustained virologic response, according to study results presented at The Liver Meeting Digital Experience.

Nearly two-thirds of patients with chronic hepatitis C infection identified via risk-based screening in the ED attended a first appointment with a provider, researchers reported at The Liver Meeting Digital Experience.

A real-world analysis has shown that a test-and-treat approach coupled with treatment with Epclusa is feasible and results in high cure rates among incarcerated patients with hepatitis C.

The majority of countries with a high burden of hepatitis C-related deaths have made little progress toward achieving the WHO goal of an at least 10% reduction in hepatitis C-related mortality by 2020, according to research presented at The Liver Meeting Digital Experience.